الفهرس 
Immune Thrombocytopenic PurpuraOnly 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Abstract
Objective This work was conducted to determine the prevalence of antiglycoprotein V in adult ITP patients and detect its impact on the outcome in these patients.
Patients and methods This was a cross-sectional study conducted on 90 patients with primary ITP who were inpatients and outpatients of hematology department at Ain - Shams University Hospitals in the period between June 2020 and December 2020 compared with 20 age-matched and sex-matched normal healthy controls. Patients were diagnosed as 1ry ITP to recent guidelines of diagnosis of ITP and 20 peron as control group. Patients’ and control group serum blood samples were collected and subjected to Human anti-glycoprotein V detection by using human anti-glycoprotein V, Platelet Antibody ELISA Kit.
Results This study Among the studied group of primary ITP patients in addition to 20 age and sex matched subjects as a control group. The mean age in the cases group was 34.82 ± 11.19 years versus 39.45 ± 12.72 years in the control group with no statistically significant difference between the two groups. There were 16 males (17.8%) and 74 females (82.2%) in the cases group while there were 6 males (30%) and 14 females (70%) in the control group. there was weak non-statistically significant positive correlation between platelets count and Anti-Glycoprotein V level antibodies in the cases group after treatment with ( p value > 0.05 ).
Conclusion we have confirmed GP V as a frequent immune target in ITP and it was demonstrated that anti-GP V autoantibodies are of clinical relevance since they can remove platelets from the circulation. But there were some limitations to our study such as low patient number and using different techniques in detecting the anti-glycoprotein V Further development of methods might be useful to increase the clinical utility of platelet autoantibody testing